You are here: Industry Insights > Prestige

News List

Akorn to Sell Consumer Health Business to Prestige Consumer Healthcare americanpharmaceuticalreview
June 02, 2021
Akorn Operating Company, a leading specialty pharmaceutical company, announced that it has entered into a definitive agreement to sell its Consumer Health business to an affiliate of Prestige Consumer Healthcare Inc. for a total enterprise value of ...
Prestige to acquire Akorn’s consumer product portfolio for $230m pharmaceutical-technology
May 31, 2021
Prestige Consumer Healthcare has agreed to acquire speciality pharmaceutical company Akorn’s Consumer Health unit for a total enterprise value of $230m in cash.
Alvotech, Prestige Biopharma Enter New Manufacturing Partnership contractpharma
August 29, 2019
Alvotech Contract Services to make one of Prestige’s biosimilar candidates.
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation b3cnewswire
July 09, 2019
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation.
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab b3cnewswire
July 09, 2019
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab.
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review b3cnewswire
May 29, 2019
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review.
Prestige, Cipla unite to sell cancer biosimilar HD201 biospectrumasia
December 17, 2018
HD201 is a mAb biosimilar to Roche’s Herceptin® which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.